Introduction
Contract manufacturing organizations (CMOs) are witnessing increased demand for outsourcing oral solid dosage (OSD), particularly from Europe. The global OSD contract manufacturing market, valued at $34.3 billion in 2022, is projected to grow at a 6.0% CAGR until 2030. Factors driving growth in OSDs include increasing complexity of new drug molecules, R&D investments by CROs/CDMOs, and rising demand for new therapies.
Technology has emerged as a key differentiator for CMOs/CDMOs. The trend is also to move away from controlled release or enteric-coated capsule delivery mechanisms to more complex dosage forms. However, concerns persist over IP protection and supply chain security when outsourcing, prompting a shift towards regionalized manufacturing hubs.
Considering India’s strengths in OSDs, the country is expected to play a vital role in the global OSD outsourcing space and derisking of global supply chains. This article explores how partnering with leading CMOs especially those headquartered in India, can drive pharma success.
Learn about Syngene’s capabilities in oral solid dosage forms.
